Quote | Pharvaris N.V. (NASDAQ:PHVS)
Last: | $22.60 |
---|---|
Change Percent: | -1.02% |
Open: | $23.77 |
Close: | $22.60 |
High: | $23.9 |
Low: | $22.475 |
Volume: | 55,487 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
News | Pharvaris N.V. (NASDAQ:PHVS)
2024-04-12 16:34:12 ET More on Pharvaris Pharvaris: Digging Deep For Sufficient Market Size Pharvaris rises as FDA lifts hold on hereditary angioedema candidate Seeking Alpha’s Quant Rating on Pharvaris Historical earnings data for Pharvaris Fi...
2024-04-10 17:05:40 ET More on Pharvaris Pharvaris: Digging Deep For Sufficient Market Size Pharvaris rises as FDA lifts hold on hereditary angioedema candidate Seeking Alpha’s Quant Rating on Pharvaris Historical earnings data for Pharvaris Fi...
Message Board Posts | Pharvaris N.V. (NASDAQ:PHVS)
Subject | By | Source | When |
---|---|---|---|
short squeeze all day | MT101 | investorshub | 06/24/2023 10:44:57 AM |
Price trading | subslover | investorshub | 06/23/2023 3:53:06 PM |
$PHVS short squeeze all day | subslover | investorshub | 06/23/2023 1:01:38 PM |
$PHVS got some short data | Pt3 | investorshub | 06/20/2023 2:31:13 AM |
MomentumIts gaining | subslover | investorshub | 06/19/2023 6:15:49 PM |
News, Short Squeeze, Breakout and More Instantly...
Pharvaris N.V. Company Name:
PHVS Stock Symbol:
NASDAQ Market:
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrolling End-of-Phase 2 meeti...
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrolling End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacks Strengthened executive committee with hiring of D...
ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral brad...